EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more
Market Cap & Net Worth: EXACT Sciences Corporation (EXAS)
EXACT Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $19.84 Billion ($19.84 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1006 globally and #782 in its home market, demonstrating a 0.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EXACT Sciences Corporation's stock price $103.94 by its total outstanding shares 190888211 (190.89 Million).
EXACT Sciences Corporation Market Cap History: 2015 to 2026
EXACT Sciences Corporation's market capitalization history from 2015 to 2026. Data shows growth from $1.76 Billion to $19.84 Billion (27.49% CAGR).
Index Memberships
EXACT Sciences Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$879.22 Billion | 2.23% | #11 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.88% | #17 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.06% | #139 of 3165 |
Weight: EXACT Sciences Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
EXACT Sciences Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EXACT Sciences Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.97x
EXACT Sciences Corporation's market cap is 5.97 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.55 Billion | $99.38 Million | -$167.21 Million | 25.66x | N/A |
| 2017 | $10.03 Billion | $265.99 Million | -$114.40 Million | 37.71x | N/A |
| 2018 | $12.05 Billion | $454.46 Million | -$175.15 Million | 26.50x | N/A |
| 2019 | $17.65 Billion | $876.29 Million | -$213.09 Million | 20.15x | N/A |
| 2020 | $25.29 Billion | $1.49 Billion | -$823.61 Million | 16.96x | N/A |
| 2021 | $14.86 Billion | $1.77 Billion | -$595.62 Million | 8.41x | N/A |
| 2022 | $9.45 Billion | $2.08 Billion | -$623.51 Million | 4.53x | N/A |
| 2023 | $14.12 Billion | $2.50 Billion | -$204.15 Million | 5.65x | N/A |
| 2024 | $10.73 Billion | $2.76 Billion | -$1.03 Billion | 3.89x | N/A |
| 2025 | $19.39 Billion | $3.25 Billion | -$207.95 Million | 5.97x | N/A |
Competitor Companies of EXAS by Market Capitalization
Companies near EXACT Sciences Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to EXACT Sciences Corporation by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
EXACT Sciences Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, EXACT Sciences Corporation's market cap moved from $1.76 Billion to $ 19.84 Billion, with a yearly change of 27.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $19.84 Billion | +2.34% |
| 2025 | $19.39 Billion | +80.74% |
| 2024 | $10.73 Billion | -24.05% |
| 2023 | $14.12 Billion | +49.42% |
| 2022 | $9.45 Billion | -36.39% |
| 2021 | $14.86 Billion | -41.26% |
| 2020 | $25.29 Billion | +43.26% |
| 2019 | $17.65 Billion | +46.56% |
| 2018 | $12.05 Billion | +20.10% |
| 2017 | $10.03 Billion | +293.26% |
| 2016 | $2.55 Billion | +44.75% |
| 2015 | $1.76 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of EXACT Sciences Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.84 Billion USD |
| MoneyControl | $19.84 Billion USD |
| MarketWatch | $19.84 Billion USD |
| marketcap.company | $19.84 Billion USD |
| Reuters | $19.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.